Phase 2
N=47
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Allergic Conjunctivitis
Bottom Line
View on ClinicalTrials.gov: NCT04622345 ↗Enrolled (actual)
47
Serious AEs
2.1%
Results posted
Sep 2025
Primary outcome: Primary: Ocular Itching as Measured by Self-reported Numerical Scales — -0.228; 0.010; -0.424; -0.035 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- VSJ-110 (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanda Pharmaceuticals
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Ocular Itching as Measured by Self-reported Numerical Scales |
-0.228; 0.010; -0.424; -0.035; -0.450; -0.182 | — |
| PRIMARY Conjunctival Redness as Measured by Investigator Assessed Numerical Scales |
-0.280; 0.075; -0.366; -0.108; -0.491; -0.151 | — |
| SECONDARY Conjunctival Redness Responder Rates as Evaluated by the Investigator Using Numerical Scales |
3; 0; 1; 0; 0; 0 | — |
Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
Eligibility Criteria
Inclusion Criteria
- At least 18 years of age of either gender and any race
- Able to provide written informed consent and sign the HIPAA form
- Willing and able to follow all instructions and attend all study visits
Exclusion Criteria
- Able and willing to avoid all disallowed medications during washout and study period
Data sourced from ClinicalTrials.gov (NCT04622345). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.